Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07306364 · ClinicalTrials.gov registry record · Phase 2
Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain
A Phase 2 study, sponsored by Yale University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT07306364 is a Phase 2 study that has not yet begun recruiting, run by Yale University. The registered enrollment target is 45 participants.
The verdict
NCT07306364, a Phase 2 study, has not yet begun recruiting, sponsored by Yale University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this research study is to investigate whether a single administration of psilocybin can improve interoceptive awareness (awareness of bodily sensations) in individuals with chronic low back pain undergoing physical therapy, and whether these improvements are linked to pain relief and better physical therapy outcomes.
Interventions
- DRUG Psilocybin 25 mg
- DRUG Psilocybin 10 mg
- DRUG Niacin 100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2026-06 |
| Est. Completion | 2029-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07306364
The ClinicalTrials.gov registry entry for NCT07306364 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Psilocybin 25 mg is the first listed.
NCT07306364 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07306364 about?
NCT07306364 is a clinical study titled "Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain". The purpose of this research study is to investigate whether a single administration of psilocybin can improve interoceptive awareness (awareness of bodily sensations) in individuals with chronic low back pain undergoing physical therapy, and whether these improvements are linked to pain relief and ...
What is the current status of trial NCT07306364?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2026-06. Estimated completion is 2029-06.
What interventions are being tested in trial NCT07306364?
The interventions under investigation include: Psilocybin 25 mg (DRUG), Psilocybin 10 mg (DRUG), Niacin 100 mg (DRUG).
Who is sponsoring clinical trial NCT07306364?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.